In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Editorial - February 2021



Dear Members,

In this newsletter we would like to focus on heart failure. Please also find below information about some of our numerous activities. I hope you enjoy one of these and I cordially invite you to actively participate in one of our activities.

In the following Professor Gianluigi Savarese has briefly and elegantly summarised data, and the awaited results of important heart failure (HF) randomised controlled trials during ESC Congress 2021.

During the ESC Congress 2020, the awaited results of important heart failure (HF) randomised controlled trials were released. Prof. Packer (Baylor University Medical, TX, USA) presented the EMPEROR-Reduced trial results which will for sure significantly contribute to reshape the treatment and the guidelines of HF.1EMPEROR-Reduced randomised 3730 symptomatic HF patients with reduced ejection fraction, i.e. EF ≤40%, with and without diabetes mellitus, to empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitors, or placebo on top of HF medical therapy. Empagliflozin was shown to significantly reduce the risk of the primary outcome, i.e. cardiovascular mortality or HF hospitalization, by 25%, with HF hospitalisation but not CV mortality individually affected.

Overall ESC Congress, although in a digital format due to the COVID-19 pandemic, has provided important new evidence which will support physicians’ efforts to improve patients’ care.

The Young community of the ESC Working Group on Cardiovascular Pharmacotherapy is termed Cardiovascular Pharmacotherapists and Trialists of Tomorrow (CPTT) and is dedicated to young professionals under 40 (physicians, nurses, scientists or others) with a special interest in cardiovascular pharmacotherapy and clinical trials. Joining the CPTT is free of charge. In order to be part of the CPTT you just need to be: a Member of the WG on Cardiovascular Pharmacotherapy (free of charge)  and be under 40 years old.

Regarding educational activities and conference, we have due to the corona pandemic successfully changed the formats to online meetings regarding the "All About Clinical Trials" (AACT), Pharmacotherapy in Older People (POP) and the Annual congress of the ESC Working Group on Cardiovascular Pharmacotherapy, the EuroCVP. Access detailed information regarding programme, dates.

On behalf of the Working Group nucleus,
Alexander Niessner, Chairperson 2020-2022

References

1. Savares; G. EHJ - Cardiovascular Pharmacotherapy, 2020; 6 (6),343–344, https://doi.org/10.1093/ehjcvp/pvaa115

2. Packer M , Anker SD , Butler J , Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigatorset al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;doi: 10.1056/NEJMoa2022190.

3. McMurray JJV , Solomon SD , Inzucchi SE , Køber L , Kosiborod MN , Martinez FA , Ponikowski P , Sabatine MS , Anand IS , BÄ›lohlávek J , Böhm M , Chiang C-E , Chopra VK , de Boer RA , Desai AS , Diez M , Drozdz J , Dukát A , Ge J , Howlett JG , Katova T , Kitakaze M , Ljungman CEA , Merkely B , Nicolau JC , O’Meara E , Petrie MC , Vinh PN , Schou M , Tereshchenko S , Verma S , Held C , DeMets DL , Docherty KF , Jhund PS , Bengtsson O , Sjöstrand M , Langkilde A-M. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008.

4. Hindricks G , Potpara T , Dagres N , Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Groupet al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;doi: 10.1093/eurheartj/ehaa612.